Non Small Cell Lung Cancer - Immunotherapy - SMARCA4 mutation

Association details:

Biomarker:	SMARCA4 mutation
Cancer:	Non Small Cell Lung Cancer
Drug Class:	Immunotherapy
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

IASLC-WCLC 2020

Title:

P75.09 - Analysis of Immune Microenvironment and Prognosis of NSCLC Patients Harbored SMARCA4 Mutation

Published date:

01/12/2021

Excerpt:

…to clarify the status of SMARCA4 mutation and its association with immune microenvironment and immunotherapy for NSCLC patients...SMARCA4 mutated NSCLC patients had worse survival and could not benefit from chemotherapy as well as immunotherapy.